Extramuraler GIST des Magens mit Manifestation durch Spontanruptur und akuter intraabdomineller Blutung mit Hämatoperitoneum

Zusammenfassung

Wir berichten über einen 38-jährigen Patienten mit einem großen extramural wachsenden gastrointestinalen Stromatumor (GIST) des Magens, der den gesamten linken Ober- und Mittelbauch einnahm und im Rahmen einer Spontanruptur mit konsekutivem Hämoperitoneum diagnostiziert wurde. Der Tumor konnte im Rahmen einer notfallmäßigen Laparotomie komplett entfernt werden. Aufgrund der Tumorruptur mit Serosadurchbruch und der histopathologischen Risikoeinschätzung als sog. high-risk GIST war eine adjuvante systemische Therapie indiziert. 

Abstract

We report on the case of a 38-year-old male ­pa­tient with a huge extramural gastrointestinal stromal tumour (GIST) of the stomach, located in the left upper and middle abdominal cavity that was diagnosed on the basis of a spontaneous ­rupture and consecutive haemoperitoneum. The lesion was resected completely in an emergency operation. The tumour was classified as a high-risk lesion for aggressive biological behaviour and with regard to tumour rupture with perforation of the serosa, an adjuvant systemic therapy was indi­cated. 

Schlüsselwörter

abdomineller Notfalleingriff - Blutung - gastrointestinaler Stroma­tumor (GIST)

Key words

abdominal surgery - bleeding - gastrointestinal stromal tumour (GIST)

Literatur

• 1 Bauer S, Hartmann J T, de Wit M et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.  Int J Cancer. 2005;  117 316-325
• 2 Blanke C D, Joensuu H, Demetri G et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Proc Am Soc Clin Oncol, GI Cancer Symposium 2004 (Abstract 2)
• 3 Cheon Y K, Jung I S, Cho Y D et al. A spontaneously ruptured gastric stromal tumor with cystic degeneration presenting as hemoperitoneum: a case report.  J Korean Med Sci. 2003;  18 751-755
• 4 DeMatteo R P, Lewis J J, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231 51-58
• 5 DeMatteo R, Owzar K, Antonescu C et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastro­intestinal stromal tumor (GIST) at high risk of recurrence: the U.S. ­Intergroup phase II trial ACOSOG Z9000. American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2008
• 6 DeMatteo R, Owzar K, Maki R American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001.  J Clin Oncol. 2007;  25 (Suppl 18) A-10079
• 7 Demetri G D, von Mehren M, Blanke C D et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  374 472-480
• 8 Fletcher C D, Berman J J, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33 459-465
• 9 Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.  Science. 1998;  279 577-580
• 10 Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations in plate­let-derived groth factor receptor a gene in gastrointestinal stromal ­tumors.  Gastroenterology. 2003;  125 660-667
• 11 Hohenberger P. Neue Konzepte der chirurgischen Therapie gastrointestinaler Stromatumore (GIST).  Viszeralchirurgie. 2003;  38 379-386
• 12 Hohenberger P, Schneider U, Pink D et al. Resection of progressive or ­residual tumor after treatment with imatinib for advanced GI stromal tumors.  Ann Surg Oncol. 2004;  11 (Suppl 2) 53
• 13 Joenssu H, Roberts P J, Sarlomo-Rikala M et al. Effect of the tyrosin ­kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  5 1052-1056
• 14 Kiura H, Yoshida T, Kinoshita S et al. Pedunculated giant gastrointestinal stromal tumor of the stomach showing extragastric growth: report of a case.  Surg Today. 2004;  34 159-162
• 15 Langer C, Gunawan B, Schüler P et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours.  Br J Surg. 2003;  90 332-339
• 16 Mehta R M, Sudheer V O, John A K. Spontaneous rupture of giant gastric stromal tumor into gastric lumen.  World J Surg Oncol. 2005;  3 11
• 17 Miettinen M, Monihan J, Sarlomo-Rikala M et al. Gastrointestinal stromal tumors / smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopthologic and immunhistochemical study of 26 cases.  Am J Surg Pathol. 1999;  23 1109-1118
• 18 Miettinen M, El-Rifai W, Sobin L H et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.  Hum Pathol. 2002;  33 478-483
• 19 Miettinen M, Sobin L H, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunhistochemical, and molecular genetic study of 1765 cases with long-term follow-up.  Am J Surg ­Pathol. 2005;  29 52-68
• 20 Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites.  Semin Diagn Pathol. 2006;  23 70-83
• 21 Ortiz-Hidalgo C, de Leon Bojorge B, Albores-Saavedra J. Stromal tumor of the gallbladder with phenotype of interstitial cells of cajal: a previ­ously unrecognized neoplasma.  Am J Surg Pathol. 2000;  24 1420-1423
• 22 Thalheimer A, Meyer D, Gattenlöhner S et al. Gastointestinaler Stromatumor der Bauchwand.  Chirurg. 2004;  75 708-712
• 23 van Oosterom A T, Judson I R, Verweij J et al. European organisation for research and treatment of cancer soft tissue and bone sarcoma group. safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.  Lancet. 2001;  358 1421-1423
• 24 van Oosterom A T, Judson I R, Verweij J European organisation for research and treatment of cancer soft tissue and bone sarcoma group et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: areport of the EORTC soft tissue and bone sarcoma group.  Eur J Cancer. 2002;  38 Suppl 5 83-87